Home > Events > Veristat to sponsorexhibit at the 5th annual crown congress clinical research operations worldwide networking

1 min read

Veristat to sponsor/exhibit at the 5th Annual CROWN Congress | Clinical Research & Operations Worldwide Networking

Email Image_CROWN CongressJoin Veristat and the industry’s elite clinical decision-makers to learn, network and discuss topics critical to the effective development, management and execution of clinical trials. Let’s assess the latest strategies, trends, tools and technologies for advancing clinical trials.

The conference will cover many topics that Veristat is well-versed in, including:

  • THE FUTURE OF MONITORING | Evaluating Monitoring Trends and Assessing Their Current and Future Impact on Clinical Operations
  • ASSESSING SITE PERFORMANCE | Optimizing Operations and Compliance at the Site Level Through Effective Performance Monitoring
  • SITE AND PATIENT ENGAGEMENT | Facilitating Engagement with Sites and Patients to Build Relationships that Optimize Clinical Trials
  • THE VALUE IN DATA | Integrating and Leveraging Data Across Trials to Transform Clinical Research
  • And many more case study presentations on outsourcing best-practices, relationship management and risk management.

 

Register Today and Save 15%Email Image_CROWN Congress_Registration Discount

If you haven’t registered yet, use the promotional code below to get a 15% discount off the standard registration cost as a “friend” of Veristat.

Veristat Discount Code:    C598VERISTAT

Stop by the Veristat booth to speak with our experts about your clinical challenges for 2016.

Schedule a meeting with us today.

 

Share This Event:

   

8 min read

Monthly FDA Guidance and Regulatory News Review - July 2026

This July 2026 regulatory update focuses on the FDA finalizing six guidances that addresses antiviral next-generation...

1 min read

Scope of Things Podcast: Daphne Smyth on the Chinese Drug Development Market Expansion

China is rapidly becoming one of the most influential forces in global drug development—but bringing innovative...